The FDA today cleared a new PET amyloid imaging agent—F-18 flutemetamol (Vizamyl). The addition of Vizamyl provides more options for dementia experts evaluating amyloid in the brain to rule out Alzheimer’s and other neurodegenerative disease.

The cognitive symptoms of autism spectrum disorder (ASD) may be due to changes in neuronal microstructures in the brain, according to a review in the October 2013 issue of Frontiers in Human Neuroscience.

Quantitative imaging with either SPECT or MR reveals the path of microspheres following liver radioembolization and could one day predict success of therapy, according to a study published Oct. 17 in the Journal of Nuclear Medicine.

An estimated 25 percent of radiation oncologists were already prescribing Radium-223 dichloride (Ra-223) injection, otherwise known as Xofigo, for metastatic castration-resistant prostate cancer one month after its launch, according to a market research report published Sept. 16 by BioTrends Research Group.

Painful rejection and other social ills prompt the same opioid response in the brain as physical pain, according to new in vivo PET neuroimaigng of snubbed subjects. 

Once limited to research novelty, PET/MR has expanded significantly, and in particular in neuroimaging applications and oncologic use—especially for imaging head and neck tumors, according to a review in the September issue of Current Radiology Reports.

Healthy elderly patients with hardened arteries were up to four times more likely to have amyloid plaque in the brain, according to research published Oct. 16 in Neurology.

Dose-intensification of systemic cancer therapy with I-131 metaiodobenzylguanidine (I-131 MIBG) may be ideal for palliative treatment of neuroendocrine tumors, according to a study published Oct. 7 in the Journal of Nuclear Medicine.